Multi-Cancer Diagnostic Tests: Global Market Outlook

Mar 2024| MDS101A| BCC Publishing

Report Highlights

This report provides an in-depth analysis of the global multi-cancer diagnostic (MCD) test market. It highlights the current and future market potential of the tests along with a detailed analysis of the drivers and challenges in the market. The report includes the company profiles of the key players with detailed information about their product portfolios and pipeline products.

Report Includes

  • An overview of the global market for the multi-cancer diagnostic tests
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Highlights of the current and future market potential of multi-cancer detection tests along with a detailed analysis of the drivers and challenges in the market
  • Estimate of the market size and revenue forecast for the global market, and corresponding market share analysis by test type, end-user, and region
  • Overview of the significant driving trends and challenges that affect the global market and its vendor landscape
  • Discussion of sustainability trends and ESG developments in the multi-cancer diagnostic tests market, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices followed
  • Information pertaining to the recent developments and upcoming technologies in the market
  • An analysis of the market competitive landscape featuring the company revenue share analyses, recent mergers and acquisition activities, and venture funding outlook
  • Company profiles of the major global players

Report Scope

The current report provides detailed exposure to the MCD test market and highlights the current and future market potential of the tests along with a detailed analysis of the drivers and challenges in the market. The report also covers market projections for 2028. The report details the market share of MCD tests based on type and end user. The market is segmented into laboratory-developed tests and in-vitro diagnostic tests based on test type. The market is segmented into diagnostic laboratories, hospitals and research institutions based on end user. The report includes the company profiles of the key players with detailed information about their product portfolios and pipeline products. The study does not include single cancer early detection tests and detection tests for targeted therapies.

The regional markets covered are U.S., Europe and emerging markets.

Revenues are broken down by region, type and end user. For market estimates, data has been provided for 2020 and 2021 as historic years, 2022 as the base year, 2023 and a forecast for 2028.

Frequently Asked Questions (FAQs)

The multi-cancer diagnostic tests market is projected to grow from $350.8 million in 2022 to $2.3 billion by 2028, at a compound annual growth rate (CAGR) of 32.3% during the forecast period.
The lack of recommended screening methods for lethal cancers and favorable government polices driving the market growth.
The market is segmented on the basis of test type, end user and region.
Laboratory developed tests (LDTs) segment will dominate the market by the end of 2028.
Exact Sciences, Grail Inc., Guardant Health, Burning Rock Biotech, and Delfi Diagnostics.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $350.8 million
Market size forecast $2.3 billion
Growth rate CAGR of 32.3% from 2023 to 2028
Units considered $ Millions
Segments covered By Test Type, End User, and Region
Regions covered The U.S., Europe, and Emerging Markets
Key Market Drivers
  • Unmet Needs in Cancer Screening
  • Government Measures for Cancer Screening
Companies studied
  • ANCHORDX MEDICAL CO. LTD.
  • BURNING ROCK BIOTECH LTD.
  • DELFI DIAGNOSTICS
  • EXACT SCIENCES CORP.
  • FREENOME HOLDINGS INC.
  • GENECAST INC.
  • GRAIL INC.
  • GUARDANT HEALTH INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Multi-Cancer Diagnostic Tests: Global Market Outlook50Free
Multi-Cancer Diagnostic Tests: Global Market Outlook

Single User License: $3500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS